Methods used by the National Animal Disease Center to test fetal calf serum for contamination with bovine viral diarrhea virus (BVDV) and antibodies against BVDV are described. Using those methods, virus was isolated from 332 of 1,608 (20.6%) lots of raw fetal calf serum obtained specifically for the Center and 93 of 190 (49%) lots of commercially available fetal calf serum. Virus neutralization and immunoperoxidase staining tests were used to detect antibodies against BVDV in 224 of the 1,608 (13.9%) lots of raw fetal calf serum. Both BVDV and antibodies against BVDV were detected in 50 lots of raw serum. The molecular specificity of antibodies against BVDV was determined by radioimmunoprecipitation. Lots of fetal calf serum that contained BVDV-specific antibodies that did not neutralize virus were identified.
The bovine viral diarrhea virus (BVDV) is ubiquitous in cattle and exists as either of 2 biotypes, noncytopathic or cytopathic, that are differentiated by cytopathic effect in cell culture. 9, 18 The developing bovine fetus is readily infected by BVDV, which replicates in several fetal cell types. 10, 11, 25, 27 Cell cultures established from infected fetuses are often infected with BVDV when initiated and remain so indefinitely. Because noncytopathic BVDV does not induce a cytopathic effect, infection of cell cultures may not be detected unless the cultures are tested by immunocytochemical procedures. In addition to infecting several fetal cell types, BVDV is found cell-free in fetal calf secreating a potential problem for diagnostic laboratories because fetal calf serum is frequently used to supplement media used for cell culture, and a variety of cell cultures from several species are susceptible to infection with BVDV. 12, 24 An undetected BVDV infection of cell cultures may complicate laboratory diagnosis of disease.
In addition to BVDV, fetal calf serum may contain antibodies against BVDV. 13, 15, 29 Those antibodies may interfere with isolation of BVDV from tissues of infected cattle or lead to false positive results in serologic or immunocytochemical tests for BVDV. The titer of stock BVDV propagated for use in diagnostic tests may be reduced by antibodies in fetal calf serum. Also, antibodies against BVDV cross-react with other pestiviruses, 6, 22, 23 namely border disease virus of sheep and hog cholera virus of swine, and may interfere with diagnosis of diseases caused by those viruses. This report describes methods currently in use at the National Animal Disease Center (NADC) to test fetal calf serum for BVDV and antibodies against BVDV. The frequencies of isolation of BVDV and detection of antibodies against BVDV in 1,608 lots of raw fetal calf serum obtained for the NADC and the frequency of isolation of BVDV from 190 lots of commercially available fetal calf serum are also reported.
Materials and methods
Fetal calf serum. Fetal calf serum was obtained for the NADC from 5 abattoirs over a period of 18 mo by a commercial supplier of raw serum. The abattoirs were located in South Dakota, Minnesota, and Illinois. Two of the abattoirs processed dairy cattle or beef heifers, exclusively. The other 3 abattoirs processed both beef and dairy cattle. Records that identified source of the fetal calf serum (dam of fetus and farm of origin) were not available. Serum from 2 or 3 fetuses was pooled by the supplier forming 1,608 lots of 1 liter each. Also, 190 lots of commercially available processed fetal calf serum were submitted to the NADC by various federal agencies over a 7-yr period for testing for adventitious virus. The number of fetuses represented and volume of those lots of commercially available serum were not known. There were 20 distributors of fetal calf serum represented in those submissions.
Virus isolation. A 50-ml sample from each liter of unprocessed pooled fetal calf serum was centrifuged at 15,000 x g for 1 hr, passaged through a 0.22-µm filter, mixed 1:1 with Eagle's minimum essential medium (MEM), and inoculated onto bovine turbinate (BT) cells grown in a 490cm 2 roller bottle. After 14 days of incubation at 37 C, the roller bottle, containing medium and cells, was frozen and thawed. A 0.1-ml aliquot of the thawed contents of the roller bottle was inoculated onto BT cells grown on multichamber glass slides. a After 48 hr of incubation at 37 C in a humidified atmosphere containing 5% CO 2 , the BT cells were fixed in acetone and tested for viral antigen by direct fluorescent antibody staining procedures. Commercially available processed fetal calf serum was similarly tested, except 850-cm 2 roller bottles were used and the inoculum was increased to 100 ml of serum mixed with an equal volume of medium.
'Virus neutralization. A standard microtitration procedure for virus neutralization was used. 26 Serial 2-fold dilutions through the 1:8 dilution of serum were made in MEM. The dilutions of serum were mixed with approximately 50 cell culture infective doses of the cytopathic BVDV-Singer isolate and incubated at 37 C in a humidified atmosphere of 5% CO,. After 1 hr, BT cells were added to mixtures of fetal calf serum and virus. After 96 hr, end points of antibody concentration were determined by microscopic examination of BT cells for cytopathic effect induced by BVDV-Singer. Some lots of serum that had titers of virus neutralizing antibodies of ≥ 8 were further tested through the 1:256 dilution of serum.
Immunoperoxidase staining. An immunoperoxidase staining procedure for detection of porcine antibodies to pestiviruses was modified for use with fetal calf serum.1 Microtitration plate wells were seeded with BT cells and incubated at 37 C in a humidified 5% CO2 atmosphere. After 24 hr, BT cells in every other microtitration plate well were inoculated with approximately 1,000 infective doses of BVDV-Singer. The BT cells in the remaining microtitration plate wells served as noninfected controls for nonspecific background staining. After a 24-hr incubation with virus, the microtitration plates were drained, rinsed twice with phosphate-buffered saline (PBS, pH 7.6), and fixed for 10 min at room temperature with 35% acetone in PBS containing 0.02% bovine serum albumin. The microtitration plates were then dried for 25 min at 37 C. A mixture of 50 µ1 of fetal calf serum and 50 µ1 of binding buffer (PBS containing 0.05% Tween 20 and 2.95% NaCl) was inoculated onto infected and noninfected cells. After 30 min incubation at room temperature, the microtitration plates were drained and washed 3 times for 2 min with wash buffer (PBS containing 0.05% Tween 20). Peroxidase-conjugated recombinant protein G b was diluted 1: 1,000 in binding buffer, and 50 µ1 of the resulting solution was added to each microtitration plate well for a 15-min incubation at room temperature. The microtitration plates were then drained and washed 2 times for 1 min each with wash buffer. Fresh substrate solution (100 µl per well) was prepared by slowly adding 10 mg of 3-amino-9-ethylcarbazole dissolved in 3 ml N,N-dimethyl-formamide to 50 ml of 0.05 M sodium acetate buffer (pH 5.0) containing 0.2 ml of 3% hydrogen peroxide. After 1 hr, the enzymatic reaction was stopped by rinsing the microtitration plates with tap water.
Radioimmunoprecipitation. Radiolabeled virus-induced
polypeptides were immunoprecipitated with selected samples of fetal calf serum and analyzed by polyacrylamide gel electrophoresis as described. 2 The sera selected contained antibodies against BVDV-Singer that were detected by both virus neutralization and immunoperoxidase staining, only by virus neutralization, or only by immunoperoxidase staining. Fluorograms were made by exposing dried gels to film c for 5 days at -90 C. Designations of virus-induced polypeptides followed those of a previous report?
Controls. The BT cells used in this study were tested and found free of adventitious BVDV by direct fluorescent antibody staining, immunoperoxidase staining, and radioimmunoprecipitation procedures. The fetal calf serum that supplemented the MEM used to grow BT cells was tested and found free of adventitious BVDV and antibodies against BVDV by the methods described here.
Results
Virus was isolated from 332 of 1,608 (20.6%) lots of raw fetal calf serum that was obtained for the NADC (Table 1) . Of those viral isolations, 330 were noncytopathic BVDV and 2 were cytopathic BVDV. Other viruses were not detected. Virus was isolated from 93 of 190 (49%) lots of commercial fetal calf serum. At least 1 lot of serum from each of 20 distributors was contaminated with virus. Of those viral isolations, 88 were noncytopathic BVDV, 2 were cytopathic BVDV, and 3 were infectious bovine rhinotracheitis virus.
Antibodies against BVDV-Singer were detected in 224 of 1,608 (13.9%) lots of raw fetal calf serum (Table  1) . Antibodies against BVDV were detected in 199 lots of serum by both virus neutralization and immunoperoxidase staining, in 12 lots only by virus neutralization, and in 13 lots only by immunoperoxidase staining. In most lots of serum that contained BVDVneutralizing antibodies, the titers of those antibodies were ≥ 8. In some lots of serum selected for further testing, the titers of BVDV-neutralizing antibodies were ≥ 256. In 15 lots of fetal calf serum, antibodies that reacted with noninfected BT cells were detected by immunoperoxidase staining (Fig. 1) . In many of those sera, virus neutralizing activity was also detected. Noncytopathic BVDV was isolated from 50 (22%) lots of raw fetal calf serum that contained antibodies against BVDV-Singer. In 42 of these sera, antibodies against BVDV were detected by both virus neutralization and immunoperoxidase staining. In 8 sera, antibodies against BVDV were detected only by immunoperoxidase staining. A total of 506 (3 1.5%) lots of raw fetal calf serum contained BVDV and/or antibodies against BVDV.
Radioimmunoprecipitation of virus-induced polypeptides was done to determine the molecular specificity of antivirus antibodies in selected lots of raw fetal calf serum (Fig. 2) . Viral polypeptides p125, p80, gp53, gp48, and gp25 were precipitated by sera that contained antibodies detected by both virus neutralization and immunoperoxidase staining. The viral polypeptides precipitated by the majority of lots of serum in which antibodies were detected only by immunoperoxidase staining were p125 and p80. Viral polypeptides gp53 and gp48, in addition to p125 and p80, were precipitated by 3 sera in which antibodies were detected by immunoperoxidase staining but not by virus neutralization. Virus-induced polypeptides were not precipitated by sera in which antibodies against virus were detected by virus neutralization but not by immunoperoxidase staining.
Discussion
The raw fetal calf serum tested in this study was for use by the NADC for research purposes and by the National Veterinary Services Laboratories for diagnostic purposes. The procedures described here for testing fetal calf serum for viral contamination have evolved over a period of several years. The method used by commercial suppliers of processed fetal calf serum to test for viral contamination is described in the Code of Federal Regulations 4 In that method, a minimum sample size of 3.75 ml (15% of ingredient in medium) is inoculated onto a 75-cm 2 or larger monolayer of cells. The inoculated cell cultures are then subpassaged twice in 21 days in the presence of sample and then tested for viral presence. We have not Label 37 marks a polypeptide of unknown origin that has been associated with BVDV infection of cells. Lanes 2 and 3 contain viral-induced polypeptides precipitated with fetal calf serum that contained antibodies against BVDV that were detected by both viral neutralization and immunoperoxidase staining. Lanes 4 and 5 show the results from precipitation of viralinduced polypeptides with fetal calf serum that contained antibodies against BVDV that were detected by only viral neutralization. Lanes 6, 7, and 8 contain viral-induced polypeptides precipitated with fetal calf serum that contained antibodies against BVDV that were detected by only immunoperoxidase staining. The arrow indicates location of gp53 in lane 8, which normally appears as a doublet with BVDV-Singer. With longer exposure of this gel to film, p125 is visible in lanes 6 and 8. found that method adequate for virus isolation from fetal calf serum. Isolation of virus from 49% of commercial lots of fetal calf serum from 20 distributors indicates that others have difficulties with that method. In the roller bottle method for virus isolation described here, a large volume of serum was inoculated onto a large number of cells, and the inoculum was constantly mixed. This probably enhanced virus contact with cells and subsequent viral infection of cells. A preference for use of roller bottles when attempting virus isolation from fetal calf serum has been reported by others. 8, 27 A virus neutralization test and an immunoperoxidase staining test were used to detect antibodies against BVDV in raw fetal calf serum. The 2 tests were complementary, as evidenced by detection of antibodies against BVDV in just the immunoperoxidase text (n = 13 sera) or in just the virus neutralization test (n = 12 sera). An explanation for detection of antibodies against BVDV by immunoperoxidase staining, but not by virus neutralization, was found on fluorograms of radioimmunoprecipitations. With such sera, the prominent, and frequently the only, viral polypeptides detected were p125 and p80. These viral polypeptides have not been associated with virus neutralization.
The BVDV polypeptide gp53 has been associated with virus neutralization. 3, 7, 19 That viral polypeptide consistently appeared on fluorograms made using serum in which antibodies against BVDV were detected by both virus neutralization and immunoperoxidase staining. The gp53 polypeptide also appeared on fluorograms from 3 lots of raw fetal calf serum in which antibodies against BVDV were detected by only immunoperoxidase staining. Detection of gp53 in certain fluorograms, using serum that did not contain detectable concentrations of virus neutralizing antibodies, might be explained by the presence of epitopes on gp53 that are not associated with virus neutralization. Another explanation is that gp53 was nonspecifically precipitated because of a close association with other viral proteins.
When antibodies against BVDV were detected by only virus neutralization, virus-induced polypeptides were not detected on fluorograms. In several of those lots of serum, however, antibodies were detected against noninfected BT cells by immunoperoxidase staining. Thus, fetal calf serum might contain antibodies that indirectly inhibit BVDV infection by reacting with BT or other bovine cells. Others also have observed nonspecific interference of BVDV growth by fetal calf serum. 8 Each lot of raw fetal calf serum was collected from 2 or 3 fetuses. Thus, the number of fetuses represented in the 1,608 lots of serum was between 3,216 and 4,824. The frequency of detection of BVDV or antibodies against BVDV in those lots of serum was ap-proximately 3 1%. The frequency of BVDV infection of fetuses represented by those sera can be roughly estimated as between 10% and 20%. These findings from small pools of raw serum obtained from 2 or 3 fetuses indicate large pools of serum obtained from many fetuses are not likely to be free of BVDV and/ or antibodies to BVDV. Isolation of BVDV from 90 of 190 (47%) lots of commercially available fetal calf serum, which contained sera from many fetuses, support that conclusion.
The high rate of contamination with BVDV and/or antibodies against BVDV that was detected in the raw fetal calf serum obtained for the NADC is important for several reasons. First, unless on-site tests are performed, veterinary diagnostic laboratories should avoid use of fetal calf serum in diagnostic procedures for pestiviral infections. Second, there is a significant risk that adventitious BVDV from fetal calf serum may lead to contamination in the veterinary biologics industry. Several reports indicate veterinary biologics have been contaminated with BVDV. 17, 28, 30 Finally, these findings indicate a high rate of fetal infection with BVDV, possibly reflecting failure to use control measures or use of inadequate control measures for BVDV in the herds from which the fetuses originated.
